The World Health Organization (WHO) defines cardiovascular diseases (CVDs) as a group of heart and blood vessel disorders that include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, and deep vein thrombosis and pulmonary embolism. According to the WHO, around 17.9 million human lives were lost due to CVDs in 2019, accounting for nearly 32% of all global deaths. The increasing prevalence of such heart-related diseases is, therefore, creating a huge requirement for transradial access devices, owing to the low cost and favorable clinical outcomes offered by them.

At present, the largescale requirement for transradial access devices is being met by Terumo Corporation, Medtronic plc, Boston Scientific Corporation, Becton, Dickinson and Company, Smiths Group plc, Teleflex Incorporated, Edwards Lifesciences Corporation, Nipro Corporation, AngioDynamics Inc., and Merit Medical Systems Inc. These companies are currently focusing on acquisitions to expand their product portfolio. For example, in October 2017, Boston Scientific Corporation acquired Apama Medical Inc. to access Apama Radiofrequency single–shot Balloon Catheter System used for treating atrial fibrillation.

Additionally, transradial access device manufacturers are heavily investing in research and development (R&D) for improving their products and developing technology for reducing fluoroscopy time and minimizing radiation exposure. Furthermore, R&D initiatives also aim to develop novel technologies to minimize radial artery injury and occlusion. Advanced devices being developed by such manufacturers will be beneficial for morbidly obese patients, geriatric patients, individuals suffering from critical vascular diseases, and people on oral anticoagulation living with a high risk of vascular access site bleeding.

Catheters, guidewires, accessories, and sheaths and sheath introducers being manufactured by the aforementioned companies are being deployed in clinics, hospitals, and ambulatory care centers (ACCs). In the coming years, catheters will be adopted at the highest rate due to the rising availability of miniaturized diagnostic catheters, such as 5F and 4F catheters, and the growing prevalence of heart diseases. These transradial access devices are used for diagnostics and testing, drug administration, blood transfusion, and fluid and nutrition administration applications.

According to P&S Intelligence, Europe led the transradial access devices market in the preceding years, due to the rising prevalence of CVDs, surging cases of cancer, and increasing acceptance of transradial intervention (TRI) as a default strategy for percutaneous coronary intervention (PCI), in the region. Additionally, the soaring number of outpatient clinics offering same-day discharge by catheterization laboratory performing TRI will also fuel the adoption of such medical devices in Europe.

Therefore, the mounting cases of heart diseases and cancer and the rising R&D activities will augment the usage of transradial access devices, globally.